Gapping up
In reaction to earnings/guidance:
- IMMR +10.5% (sees Q2 EPS and revs above consensus), SGH +5.4%, SAND +1.4% (provides Q2 operational update), MSM +1.3%
Other news:
- ONCS +28.7% (announces clinical trial collaboration and supply agreement with MRK)
- SBTX +25.1% (announces a clinical supply agreement with Regeneron (REGN) for Libtayo)
- BHVN +11.5% (reported $93 million in net product revenue from sales of NURTEC ODT in the second quarter of 2021)
- XBIT +10.7% (declares extraordinary cash dividend of ~$2.50/sh)
- USAS +8.9% (signed an agreement with the Mexican Ministries of Economy, Interior and Labour committing to a reopening at the Cosalá Operations shut for over 17 months by an illegal blockade)
- SEEL +5.9% (reports preliminary findings supporting advancement of SLS-004 program into additional preclinical studies of Parkinson's Disease)
- BFRA +3.9% (seeks IPO in the USA)
- ELYS +3.5% (to acquire U.S. Bookmaking)
- WPRT +3% (Westport Fuel Systems, TUPY, and AVL to collaborate in demonstration of world's most efficient hydrogen-fueled internal combustion engine)
- UUUU +2.3% (Energy Fuels and Neo Performance Materials announce contract signing and launch of commercial shipments of rare earth product to Europe in emerging U.S.-based rare earth supply chain)
- ATHN +2.3% (announces business combination with Heliogen)
- ELOX +2.1% (enrolls sufficient number of patients to assess biological activity of ELX-02)
- DMYQ +1.9% (Planet to become publicly traded company through merger with dMY IV)
- CFMS +1.9% (settles patent litigation with Wright Medical)
- STLD +1.7% (authorizes an additional $1 bln share repurchase program)
- STAR +1.1% (to explore market interest for its net lease assets)
Analyst comments:
- CCXI +3.1% (upgraded to Buy from Hold at Stifel)
- ATI +1.4% (upgraded to Neutral from Underperform at BofA Securities)